Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.

Abstract: A traction device for enhancing vehicular traction, aiding in the extraction of vehicles stuck in challenging terrains such as mud, snow, or ice. The device has a rectangular mesh configuration, comprised of longitudinal chains and lateral chains. The device further includes a plurality of parallel lateral chains extending across the longitudinal chains for providing support to the device. A plurality of pegs and pins are used for securing the device to a terrain in which the vehicle is stuck. A handle of the device touches the front tire and another handle touches the rear tire. The traction device has a length from about 90% to about 100% of the vehicle's wheelbase, and the mesh width, ranges from 6 to 24 inches, to accommodate various tire widths.

Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.

Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.

Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.

Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.

Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.

Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.

Abstract: Systems, apparatuses, methods discussed herein provide insurance claims adjusters with the ability to quickly label numerous photographs associated with an insurance claim. For instance, a photograph label claims tool may be installed on a computing device of the insurance claims adjuster. The photograph label claims tool may facilitate labeling and formatting of photographs taken by the insurance claims adjuster of damaged property items, which may be used to settle an insurance claim. The photograph label claims tool may then generate a document (e.g., a PDF) including each of the labeled photographs and transmit the document to an insurance provider.

Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.

Abstract: The present invention is directed to improved screen printing squeegee blades, which include a first end, a second end, a top portion for receipt by a blade holder, a bottom portion adapted for contacting the screen of a screen printing press along at least one printing edge, a front face, a back surface, and a buckle control channel formed in either the front face or the back surface.

Abstract: The present invention is directed to improved screen printing squeegee blades, which include a first end, a second end, a top portion for receipt by a blade holder, a bottom portion adapted for contacting the screen of a screen printing press along at least one printing edge, a front face, a back surface, and a buckle control channel formed in either the front face or the back surface.

Abstract: A turbine (5) having at least two sets of co-axially mounted, rotatable blades (10, 15) arranged so that one set cannot eclipse another. Preferably, the sets of blades (10, 15) are contra-rotatable. Each set of blades (10, 15) may be operable to extract similar amounts of energy, thereby to minimise the net reactive torque.

Abstract: This invention relates to unsubstituted and polymeric leuco colorants for use as consumer product additives to indicate a product function by color change, to make attractive or distinctive visual effects, or to provide latent or delayed color generation. The colorants may be present in a stable, colorless state and may be transformed to an intense colored state upon exposure to certain physical or chemical changes. Alternatively, the colorants may be transformed from one color to another color upon exposure to certain physical or chemical changes. The colored form of the unsubstituted or polymeric leuco colorant may be transient, since the colorant can revert back to its colorless form or its original color after the physical or chemical activation has been removed or changed. Polymeric leuco colorants are typically comprised of at least two components: at least one leuco chromophore component and at least one polymeric component.

Abstract: A turbine (5) having at least two sets of co-axially mounted, rotatable blades (10, 15) arranged so that one set cannot eclipse another. Preferably, the sets of blades (10, 15) are contra-rotatable. Each set of blades (10, 15) may be operable to extract similar amounts of energy, thereby to minimise the net reactive torque.

Abstract: This invention relates to unsubstituted and polymeric leuco colorants for use as consumer product additives to indicate a product function by color change, to make attractive or distinctive visual effects, or to provide latent or delayed color generation. The colorants may be present in a stable, colorless state and may be transformed to an intense colored state upon exposure to certain physical or chemical changes. Alternatively, the colorants may be transformed from one color to another color upon exposure to certain physical or chemical changes. The colored form of the unsubstituted or polymeric leuco colorant may be transient, since the colorant can revert back to its colorless form or its original color after the physical or chemical activation has been removed or changed. Polymeric leuco colorants are typically comprised of at least two components: at least one leuco chromophore component and at least one polymeric component.

Abstract: A feed-forward amplifier (600) has an error path (123) replaced by a feed-forward amplifier (603) in a nested feed-forward configuration. By replacing the error path (123) with the feed-forward amplifier (603), design parameters such as efficiency and power output which are difficult to achieve with the conventional error path (123) are easily achieved with the single loop feed-forward amplifier (603). In this configuration, the main path (613) of the feed-forward amplifier (603) is capable of operating in a more efficient Class AB mode while still operating over a large dynamic range with to provide a relatively constant gain/phase relationship, thus insuring good intermodulation performance. The error path (627) of the feed-forward amplifier (603) must still be biased Class A, but it's requirements are much less than those of a Class A error amplifier (124) in an un-nested configuration.

Abstract: A method of manufacturing, extruding, milling and welding a high torque, thin monolithic walled guiding catheter having resilient reinforcement material (8, 23, 29, 70, 73) integrally spiralled or braided into monolithic walls (21) of flexible material. A solid lubricant, also referred to as dry lubricant, comprised of either special fluorine containing materials or polymeric organic silicon compounds is embedded into interior and exterior wall surfaces of the catheters. Smooth interior walls (11) are channeled (10) to decrease friction resistance, to trap resistance particles and to dissipate friction heat in the high ratio of surface area to cross-sectional area of small catheters. Number of spirals or braids of reinforcement strands per unit of length, number of layers of strands of the catheters, catheter diameter and progressiveness thereof are designedly different for separate portions of particular catheters.